Patents have evolved to become more than tools to be weaponized against a patent owner’s direct competitors on an as-needed basis. Patents are used more and more to generate significant additional return on research and development costs through licensing and, in an increasingly knowledge-based economy, to moderate the growth of competitors by increasing the cost of doing business in a field, particularly in patent-intensive industries. In the life sciences sector, studies have shown that licensors consistently profit from licensing to a competitor, even for small technological leads.
With that in mind, Womble Bond Dickinson attorneys Casey Donahoe and John Cox have written a new article on “Considerations for Leveraging IP in the Life Sciences Sector.” The article has been published by the National Law Review – click here to read the full article.
Casey Donahoe, Ph.D., practices intellectual property law with an emphasis on patent prosecution and strategy in the fields of biotechnology, life sciences and medical devices. A highly versatile patent practitioner with a broad scientific background, he works with a range of technologies at all stages of patent prosecution, and counsels his clients on patent filing and claim strategies, and trademark use.
John Cox, Ph.D., counsels and represents clients in patent litigation related to chemical, biotechnology, medical device, and pharmaceutical matters and has significant experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations. John has dealt with subject matter ranging from brain chemistry, the gastrointestinal system, and drug delivery systems to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products.